// App-Quantinova.ai

1412 : Patient Expectations and Perceptions of Treatment in CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma

Researchers

Presenter

  • Adam D. Cohen

Principal Investigators

  • Myo Htut

  • Jesus G. Berdeja

  • Deepu Madduri

  • Saad Z. Usmani

  • Alicia J. Allred

  • Yunsi Olyslager

  • Arnob Banerjee

  • Jenna D. Goldberg

  • Jordan M. Schecter

  • Carolyn C. Jackson

  • Katharine S. Gries

  • John Fastenau

  • William Deraedt

  • Marlene J. Carrasco

  • Muhammad Akram

  • Farah Hossain

  • Sigrid Crawford

  • Ross Morrison

  • Lynda Doward

  • Andrzej Jakubowiak

  • Sundar Jagannath

Medical Centers

  • University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA

  • Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI

  • City of Hope Comprehensive Cancer Center, Monrovia, CA

  • Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN

  • Mount Sinai Medical Center, New York, NY

  • Levine Cancer Institute, Charlotte, SC

  • Janssen, Spring House, PA

  • Janssen R&D BE, Beerse, Belgium.

  • Janssen R&D, Raritan, NJ

  • Janssen Global Services, Raritan, NJ

  • Legend Biotech USA Inc., Piscataway, NJ

  • RTI Health Solutions, Manchester, United Kingdom

  • The University of Chicago Medical Center, Chicago, IL

  • Department of Medicine/Hematology/Oncology, Mount Sinai Medical Center, New York, NY

Locations

  • United States

  • Belgium

  • United Kingdom

Companies

  • RTI Health Solutions

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • Coxsackie Virus And Adenovirus Receptor

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • fludarabine tablet

Outcome

  • N/A

Study Design

  • Multinational

Phase

  • I

Study Id's

  • NCT03548207

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved